Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled Study, to Evaluate the Efficacy and Safety of Janagliflozin (25 mg and 50 mg) as Monotherapy in Chinese Patients Diagnosed With T2DM

NCT03811548 is registered in ClinicalTrials.gov with Sihuan Pharmaceutical Holdings Group Ltd. as lead sponsor.

NCT NCT03811548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03811548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled Study, to Evaluate the Efficacy and Safety of Janagliflozin (25 mg and 50 mg) as Monotherapy in Chinese Patients Diagnosed With T2DM
Lead sponsor
Sihuan Pharmaceutical Holdings Group Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
May 23, 2019
Completion date
December 31, 2020
Enrollment
442 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes type 2